Pascalle S. Monraats

Author

Leiden University Medical Center

Also Known As

P S Monraats, P. S. Monraats, P.S Monraats, P.S. Monraats, Pascalle Monraats, Pascalle S Monraats, Pascalle S. Monraats

Publications

503

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center University Medical Center Utrecht Amsterdam UMC Location University of Amsterdam Erasmus MC Netherlands Heart Institute

About

Pascalle S. Monraats is an author at Leiden University Medical Center specializing in vascular biology, atherosclerosis, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	175
2	Public Health	4	4	138
3	Epidemiology	4	4	138
4	Cell Biology	1	1	80
5	Diabetes	1	1	11

Pascalle S. Monraats

Publications

464

Citations

H-Index

Page 1

	Year	Citations
Tumor necrosis factor‐α plays an important role in restenosis development Pascalle S. Monraats, Nuno Pires, Abbey Schepers, The FASEB Journal Vascular DiseaseImmunologyGenetic EpidemiologyPathologyTnfalpha Gene	2005	80
Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions Pascalle S. Monraats, Nuno Pires, Willem R.P. Agema, Circulation	2005	68
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention Pascalle S. Monraats, Yue Fang, Douwe Pons, Expert Opinion on Therapeutic Targets	2010	43
Metabolic Syndrome and Risk of Restenosis in Patients Undergoing Percutaneous Coronary Intervention Jamal S. Rana, Pascalle S. Monraats, Aeilko H. Zwinderman, Diabetes Care	2005	41
The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice D. Eefting, Abbey Schepers, Margreet R. de Vries, Atherosclerosis InflammationCytokineNeointima FormationImmunologyPathology	2006	37
Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention Pascalle S. Monraats, F. A. S. Kurreeman, Douwe Pons, Genes and Immunity InflammationPercutaneous Coronary InterventionCardiovascular DiseaseNew Risk MarkerImmunology	2006	37
Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions Goran Rudež, Douwe Pons, Frank W.G. Leebeek, Human Mutation	2008	34
Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1 Jasper S. Wijpkema, Paul L. van Haelst, Pascalle S. Monraats, Pharmacogenetics and Genomics	2006	33
–455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement Pascalle S. Monraats, Jamal S. Rana, Aeilko H. Zwinderman, Thrombosis and Haemostasis	2005	23
Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies Douwe Pons, Stella Trompet, Anton J. M. de Craen, Heart	2010	21

Page 1